Virtus ETF Advisers LLC Chinook Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $33,543 - $41,754	-1,558 Reduced 27.77%	4,052 $93,000
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $16,394 - $24,068	-880 Reduced 13.56%	5,610 $146,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $857 - $1,145	49 Added 0.76%	6,490 $128,000
Q2 2022 Aug 12, 2022	SELL	$12.59 - $18.8 $51,556 - $76,986	-4,095 Reduced 38.87%	6,441 $113,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $7,476 - $10,381	-622 Reduced 5.57%	10,536 $172,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $15,757 - $24,807	-1,474 Reduced 11.67%	11,158 $182,000
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $7,670 - $9,911	-667 Reduced 5.02%	12,632 $161,000
Q2 2021 Aug 10, 2021	BUY	$13.6 - $18.98 $180,866 - $252,415	13,299 New	13,299 $188,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.